ActiveMonitor
Save

Pharmacokinetics for Experimental Rheumatoid Arthritis Treatment

Veterans Affairs (VA)
8(a)HUBZoneSDVOSBWOSB

Informational notice — track for solicitation

This opportunity is not yet open for proposals. Use this time to prepare — engaging early (capability statement, contacting the agency) can position you for the upcoming solicitation.

Want to track notices like this?

Get your fit score, win probability, and required capabilities.

Fit Score7/10Consider

Contract Details

Value
Similar contracts award $25K to $115K (median $58K, 570 awards)
NAICS Codes
Set-Asides
8(a), HUBZone, SDVOSB, WOSB

Agency & Contact

Contracting Organization

Agency
VETERANS AFFAIRS, DEPARTMENT OF

Point of Contact

John A. Smith
Contracting Officer
(202) 555-0100

Key Dates

Published8d ago
Jul 16, 2026
Last Updated8d ago
Jul 16, 2026
Became Presolicitation7d ago
Jul 16, 2026
Tracked
Response Duein 24d
Aug 17, 2026

Description

Department of Veterans Affairs Network

Contracting Office (NCO) 05 Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics 1. Purpose This Sources Sought Notice is issued solely for market research in accordance with FAR Part 10.

This is not a solicitation, and it does not commit the Government to issue a solicitation or make an award. The Department of Veterans Affairs (VA) seeks to identify qualified vendors capable of performing preclinical toxicology and pharmacokinetic (PK) studies on an experimental Rheumatoid Arthritis treatment involving peptide-displaying liposomes containing dexamethasone. 2. Requirement Overview The VA requires a contractor to perform GLP-compliant toxicity testing and GLP or non GLP pharmacokinetic studies in adult rats. These studies support advancement toward a future FDA Pre IND meeting for the patented joint-targeted liposomal delivery system developed under prior VA-funded research. 3. Summary of Required Services

A. Toxicity Studies (GLP Required) Receive peptide displaying liposomes containing 150 mg dexamethasone, 80% encapsulation efficiency, with Certificate of Analysis. Conduct single dose intravenous toxicity testing in 20 32 rats (male and female). Record clinical observations, weight, and food intake over a 14 day period. Conduct blood testing for organ damage markers (liver, kidney, heart, muscle, etc.). Perform euthanasia, necropsy, and histopathology of major organs.

B. Pharmacokinetic (PK) Studies (GLP or non GLP) Administer single IV doses to 12 24 rats (balanced sexes). Observe and weigh animals before and after dosing. Collect blood samples at 8 10 defined time points (10 min through 48 hours). Process plasma and store at 20°C. Perform chemical extraction and LC MS/MS quantification of dexamethasone and metabolite 6 hydroxydexamethasone (6OHDEX). Generate PK parameters (t½, Cmax, AUC, etc.).

C. Final Deliverable Comprehensive written report summarizing toxicity, PK parameters, and analytical results. 4.

Get matched to contracts like this daily

Free AI-powered contract matching for your business.